However, due to reported side effects and unfavorable pharmacokinetics, much effort has been made to develop novel selective and better bioavailable HDAC inhibitors against several diseases such as cancer, parasitic diseases, inflammation, and others [26,27,28,29]. This evidence concerns the gene HDAC9 and cancer.